Elekta shared a post on LinkedIn:
“Today in Kolkata at the 45th Annual Conference of the Association of Radiation Oncologists of India (AROICON 2025), we had the pleasure of introducing our latest linac, Elekta Evo*, to the Indian market.
Reflecting on this milestone, Shankar S., Elekta’s Vice President, India, shared:
“Evo is uniquely positioned to address India’s growing cancer burden and evolving patient needs, and its arrival in India marks a significant milestone, as it will help accelerate our growth in the region.”
*Elekta Evo has Central Drugs Standard Control Organization (CDSCO) registration, CE mark and is pending U.S. FDA 510(k) clearance with limited global distribution. Do not distribute this information within the U.S.”
More posts featuring Elekta on OncoDaily.
